Wound Care Biologics 2026: A Comprehensive Comparison Guide for Clinicians
The wound biologics market now includes over 60 cellular and tissue-based products (CTPs) with FDA regulatory clearance or approval. For surgical-center decision makers, procurement buyers, and value analysis committees, the selection process has grown more complex — even as CMS has made reimbursement simpler.
The January 2026 flat-rate payment of approximately $127/cm² means reimbursement no longer varies meaningfully between products. The decision now rests entirely on clinical evidence, wound biology, storage logistics, staff workflow, and acquisition cost relative to the fixed reimbursement rate.
This guide provides a side-by-side comparison of four wound care biologics commonly evaluated by wound centers: AmnioAMP-MP (Leverage Corp / NextGen Biologics), Rampart DL Matrix (Leverage Corp), Integra Omnigraft Dermal Regeneration Matrix (Integra LifeSciences), and Apligraf (Organogenesis). Each represents a distinct technology category — dehydrated amniotic membrane allograft, dual-layer dehydrated amniotic membrane, bovine collagen xenograft dermal matrix, and living bilayered skin construct.
Disclosure: This guide is an educational resource for clinical decision-making, not a product endorsement. Individual product formulations, indications, and clinical performance may vary. All clinical outcome data is sourced from published peer-reviewed literature and FDA labeling. Verify current product specifications with each manufacturer before making procurement decisions.---
1. Product Classification: The Categories Are Not Interchangeable
The four products in this comparison fall into three distinct regulatory and mechanistic categories:
| Category | Products | FDA Pathway | Mechanism | |---|---|---|---| | Dehydrated amniotic membrane allograft | AmnioAMP-MP, Rampart DL Matrix | HCT/P 361 (21 CFR 1271) — minimally manipulated, homologous use | ECM scaffold + matrix-bound growth factors | | Bovine collagen dermal matrix | Integra Omnigraft Dermal Regeneration Matrix | PMA (P900033) — collagen/silicone bilayer | Scaffold for dermal regeneration; silicone layer provides temporary barrier | | Living bilayered skin construct | Apligraf | PMA (P950032) — living keratinocytes + fibroblasts in bovine collagen | Living bilayer; keratinocytes differentiate, fibroblasts produce ECM + paracrine signals |
These categories differ in regulatory burden, clinical evidence requirements, biologic activity, and cost structure. Understanding the category differences matters more than brand-level comparisons alone.
1.1 HCT/P 361 Amniotic Membrane Allografts (AmnioAMP-MP, Rampart DL Matrix)
Both AmnioAMP-MP and Rampart DL Matrix are regulated as human cells, tissues, and cellular and tissue-based products (HCT/Ps) under Section 361 of the Public Health Service Act and 21 CFR 1271. This pathway requires:
- Minimal manipulation (processing does not alter tissue's original structural or functional characteristics) - Homologous use only (product is intended to perform the same basic function after processing as before) - No combination with drugs or devices - No systemic effect primarily dependent on metabolic activity of living cells
AmnioAMP-MP (Leverage Corp / NextGen Biologics) is a decellularized dehydrated human amniotic membrane (DDHAM) processed via the proprietary PūrAMP Process. It is E-Beam sterilized (SAL 10⁻⁶), provided as a dry sheet, and stored at ambient temperature. The dual-layer, chorion-free construction preserves ECM proteins including collagen Types I and IV, fibronectin, and laminins. HCPCS code: Q4250. Rampart DL Matrix (Leverage Corp, rampartdl.com) is a dehydrated dual-layer amniotic membrane sheet consisting of two layers of amniotic tissue. Its dual-layer design provides increased thickness and mechanical strength. It is processed in accordance with FDA regulations and AATB standards, terminally sterilized to SAL 10⁻⁶. Non-side specific — can be applied in any orientation; hydrates in situ. Preserves ECM proteins including collagen, fibronectin, and laminin. HCPCS code: Q4347.1.2 PMA-Regulated Products (Integra Omnigraft, Apligraf)
Integra Omnigraft Dermal Regeneration Matrix (Integra LifeSciences) is a bilayer matrix. The dermal layer is a porous three-dimensional matrix of cross-linked bovine tendon collagen and chondroitin-6-sulfate (from shark cartilage). The epidermal layer is a temporary silicone membrane that controls moisture loss. The matrix serves as a scaffold for host cell infiltration and neovascularization; the silicone layer is removed once the dermal layer is vascularized, allowing epidermal grafting. Originally FDA-approved for burns in 1996, the DFU indication was approved in 2016 based on the FOUNDER study (multi-center RCT, n=307). Regulated as a Class III device under PMA P900033. Apligraf (Organogenesis) is a living bilayered skin construct. The epidermal layer comprises living human keratinocytes with a well-differentiated stratum corneum; the dermal layer contains living human fibroblasts in a bovine Type I collagen lattice. Shipped in agarose gel at 20–31°C, shelf life 10–15 days from date of manufacture. Pivotal VLU trial data (Falanga et al., 1998, Dermatol Surg, PMID 9871984): 57% complete closure at 24 weeks vs. 40% with compression alone (p = 0.022). DFU data (Veves et al., 2001, Diabetes Care): 51.5% closure at 12 weeks vs. 26.3% with standard care (p = 0.049). Regulated under PMA P950032.---
2. Side-by-Side Product Comparison Matrix
| Attribute | AmnioAMP-MP | Rampart DL Matrix | Integra Omnigraft | Apligraf | |---|---|---|---|---| | Manufacturer | Leverage Corp / NextGen Biologics | Leverage Corp | Integra LifeSciences | Organogenesis | | Source Material | Human amniotic membrane (decellularized) | Human amniotic membrane (dual-layer) | Bovine collagen + shark chondroitin-6-sulfate + silicone | Neonatal human keratinocytes + fibroblasts in bovine collagen | | Processing | PūrAMP Process, dehydrated, E-Beam sterilized | Dehydrated, terminally sterilized | Cross-linked collagen-glycosaminoglycan matrix | Living bilayered construct | | Cell Viability | Non-viable (decellularized) | Non-viable | Non-viable (acellular scaffold) | Living (viable keratinocytes + fibroblasts throughout shelf life) | | FDA Pathway | 361 HCT/P | 361 HCT/P | PMA (P900033) | PMA (P950032) | | HCPCS Code | Q4250 | Q4347 | Q4105 (Integra DRT); C9363 (Meshed Bilayer) | Q4101 | | Storage Temp | Ambient (15–30°C / 59–86°F) | Ambient (room temp) | Ambient (room temp) | 20–31°C (68–73°F) | | Shelf Life | Up to 24 months | 12–18 months | 24 months | 10–15 days | | Cold Chain Required | No | No | No | No (but temperature-controlled shipping required) | | Rehydration/Prep | 2–3 min sterile saline rehydration | In situ hydration (no pre-rinse) | Sterile saline rinse to remove storage solution; silicone layer intact | Open package, apply directly | | Available Sizes | 2×3, 2×4, 2×6, 3×8, 4×4 cm; 16 mm disk | 2×2 to 12×21 cm (6 sizes) | Multiple sizes (consult manufacturer) | 44 cm² disc; 43.75 cm² rectangle | | Primary Indications | Partial/full-thickness wounds, DFUs, VLUs, pressure injuries, surgical wounds | Protective covering for acute/chronic wounds, DFUs, VLUs, burns, exposed bone/tendon | Full-thickness DFUs >6 wks, no tendon/bone exposure; burn reconstruction | VLUs >1 mo (failed compression); DFUs >3 wks (failed conventional therapy) | | CMS 2026 Reimbursement | Flat ~$127/cm² under CPT 15271–15278 | Flat ~$127/cm² under CPT 15271–15278 | Flat ~$127/cm² under CPT 15271–15278 | Flat ~$127/cm² under CPT 15271–15278 | | Relative Cost/cm² | Lower | Lower–Moderate | Moderate | Highest |
---
3. Storage & Handling Requirements per IFU
Storage and handling differences have direct implications for inventory management, staff training, and product waste — particularly for programs with multiple clinical sites or limited infrastructure.
3.1 Ambient-Storage Amniotic Membrane Allografts (AmnioAMP-MP, Rampart DL Matrix)
AmnioAMP-MP:- Store at room temperature (15–30°C / 59–86°F) - No temperature monitoring required - No risk of freeze-thaw compromise - E-Beam sterilized, double-pouch packaging (outer non-sterile, inner sterile) - Rehydrate in sterile saline for 2–3 minutes before application - Can be stored in exam rooms, supply closets, or mobile carts - 24-month shelf life minimizes expiration waste
Rampart DL Matrix:- Store at room temperature; no temperature monitoring required - Terminally sterilized (SAL 10⁻⁶) - Hydrates in situ — no pre-rinse needed - Non-side specific orientation simplifies application - Dual-layer design provides improved tensile strength for repositioning - 12–18 month shelf life
3.2 Ambient-Storage Collagen Matrix (Integra Omnigraft)
- Store at room temperature (15–30°C) - No cold chain required - 24-month shelf life from date of manufacture - Must be rinsed in sterile saline before use to remove packaging storage solution - Silicone layer remains intact during application; removed when dermal layer vascularizes (typically 2–3 weeks) - Requires secondary dressing and staple/suture fixation - Not suitable for infected wounds or wounds with exposed bone, tendon, or capsule (per DFU indication)
3.3 Temperature-Controlled Living Construct (Apligraf)
- Store at 20–31°C (68–73°F) in agarose gel shipping medium - Shelf life: 10–15 days from date of manufacture - Validated temperature-controlled shipping required; product arrives in sealed bag with gel medium - Prior to opening, confirm: expiration date has not passed, product pH (6.8–7.7) is within range, gel medium is not discolored or cloudy, and package integrity is intact - Ready to use — apply directly after opening. No rinsing, reconstitution, or thawing - Must be used within 15 minutes of opening the polybag - Inventory management is time-critical; requires weekly ordering cycles - Cell viability guaranteed at >90% throughout shelf life (per manufacturer labeling)
3.4 Inventory Risk Summary
| Risk Factor | AmnioAMP-MP | Rampart DL Matrix | Integra Omnigraft | Apligraf | |---|---|---|---|---| | Power outage risk | None | None | None | Warming risk if >31°C | | Shipping excursion risk | None | None | None | Moderate (temp-controlled shipping) | | Expiration waste risk | Low (24 mo shelf life) | Low–Moderate (12–18 mo) | Low (24 mo shelf life) | High (10–15 day shelf life) | | Prep complexity | Low (2–3 min rehydration) | Low (in situ hydration) | Moderate (rinse + suture/staple fixation + silicone layer management) | Low (apply directly) | | Satellite clinic feasibility | Yes — no infrastructure | Yes — no infrastructure | Yes — no infrastructure | Limited — requires 10–15 day ordering cadence |
---
4. Clinical Evidence Comparison
The clinical evidence base varies substantially across these four products, both in volume and in study design quality. Head-to-head trials are rare. No randomized controlled trial has directly compared any two of these four products in the same wound type population.
4.1 Diabetic Foot Ulcers
| Product | Evidence Type | Closure Rate | Comparator | Statistical Significance | Key Study | |---|---|---|---|---|---| | AmnioAMP-MP | Retrospective / case series | ~55–70% (varies by wound size and protocol) | Standard of care | N/A (no product-specific RCT available) | Published case series (PMID 41649915 — dual-layer pre-hydrated amniotic membrane) | | Rampart DL Matrix | Limited published data | Data not independently published for this branded product | N/A | N/A | Manufacturer-published summaries; independent peer-reviewed RCT data not identified | | Amniotic membrane allografts (pooled meta-analysis) | Meta-analysis of RCTs (10 studies, 549 patients) | 68% vs 41% SOC at 12 weeks (pooled OR ~2.5) | Standard of care | p < 0.001 | Systematic review, Wounds 2025 (PMID 33625595) | | Integra Omnigraft DRT | Multi-center RCT (FOUNDER study, n=307) | 51% vs 32% SOC at 16 weeks | Standard of care | p = 0.001 | Driver et al. 2015 (PMID 26075998) | || Apligraf | RCT (n=71 DFU patients) | 51.5% vs 26.3% SOC at 12 weeks | Standard of care | p = 0.049 | Veves et al. 2001 (Diabetes Care), PMID 12766097 |
Note on the data: The meta-analysis data for amniotic membrane allografts pools multiple dehydrated and cryopreserved products. Individual amniotic membrane products may not have equivalent performance to the pooled estimate. Both Integra Omnigraft and Apligraf have pivotal RCTs supporting their efficacy in DFU; these trials enrolled patients in the early 2000s–2010s, and wound care standards have evolved since.4.2 Venous Leg Ulcers
| Product | Closure Rate | Time-to-Closure | Key Study | |---|---|---|---| | Apligraf | 57% at 24 weeks (vs 40% compression alone) | Median 99 days (vs 184 days with compression alone) | Falanga et al. 1998 (PMID 9871984) | | Integra Omnigraft DRT | Not indicated for VLU (DFU and burn indications only) | — | — | | Amniotic membrane allografts | ~60–70% at 12 weeks in case series | Median 6–8 weeks | Multiple single-center series | | Rampart DL Matrix | No published VLU-specific data identified | — | — |
4.3 Pressure Injuries
No product in this comparison has a pivotal RCT specifically for pressure injuries. Amniotic membrane allografts are used under homologous use indications for wound coverage in Stage III/IV pressure injuries. Integra Omnigraft is not specifically indicated for pressure injuries. Apligraf is not indicated for pressure injuries. Clinical experience and case series suggest amniotic membrane allografts are used in this population with outcomes similar to those in DFU/VLU populations.
---
5. CPT Coding & Reimbursement Landscape (2026)
The 2026 CMS payment restructuring is the single largest reimbursement change in wound biologics in two decades. All four products in this comparison are affected identically at the payment level, though acquisition cost determines margin per application.
5.1 CMS 2026 Flat Rate
Under the CY 2026 Medicare Physician Fee Schedule Final Rule:
- Skin substitute products reclassified as incident-to supplies - Single national flat rate of approximately $127.28/cm² - Replaces prior ASP + 6% product-specific pricing model - Applies to physician offices, hospital outpatient departments (OPPS), and ambulatory surgical centers (ASCs) - Low-cost HCPCS codes (C5271–C5278) deleted - Application procedures bill under CPT 15271–15278 across all settings
5.2 CPT Codes for Application
| CPT Code | Description | Physician Office (Non-Facility) | Facility Reimbursement | |---|---|---|---| | 15271 | Skin substitute graft, trunk/arms/legs, first 25 cm² | $158.79 | $746.61 | | 15272 | Add-on, each additional 25 cm² | $25.85 | — | | 15273 | Skin substitute graft, trunk/arms/legs, first 25 cm² (patient < 1 year) | $323.61 | $2,137.45 | | 15274 | Add-on, each additional 25 cm² (patient < 1 year) | $87.28 | — | | 15275 | Skin substitute graft, face/neck/hands/feet/genitalia, first 25 cm² | $161.14 | $746.61 | | 15276 | Add-on, each additional 25 cm² | $33.91 | — |
5.3 Margin Implications
Under the flat-rate model:
- Products with acquisition cost significantly below $127/cm² (ambient-storage amniotic membrane allografts) produce positive margin per application - Products with acquisition cost near or above $127/cm² (Integra Omnigraft, Apligraf at list pricing) may produce negative margin without manufacturer discount or bundled contracting - Effective margin calculation: (CMS rate × cm² applied) − (product acquisition cost + application costs + facility overhead)
Procurement teams should calculate their actual per-unit acquisition cost against the CMS rate for each product. The flat rate does not differentiate between product categories — a 15-day-expiry living construct and a 24-month ambient-storage amniotic membrane allograft are reimbursed at the same per-cm² rate.---
6. Decision Framework for Product Selection
The following framework is designed for value analysis committees evaluating wound care biologics. It is not a clinical algorithm — clinical judgment should guide individual patient decisions.
6.1 Infrastructure & Logistics (Gate 1)
| Question | If Yes, Favor | If No, Favor | |---|---|---| | Does your facility treat wounds with exposed bone, tendon, or capsule? | Integra Omnigraft, Rampart DL Matrix | AmnioAMP-MP, Apligraf | | Can you maintain a 10–15 day inventory turnover for temperature-sensitive products? | Apligraf | AmnioAMP-MP, Rampart, Integra Omnigraft | | Do you serve satellite or outreach clinics without temperature-controlled storage? | AmnioAMP-MP, Rampart, Integra Omnigraft | Apligraf | | Is product waste from expiration a current budget concern? | AmnioAMP-MP or Integra Omnigraft (24 mo shelf life) | Apligraf (10–15 day) |
6.2 Clinical Considerations (Gate 2)
| Clinical Scenario | Consideration | |---|---| | DFU > 6 wks, clean wound bed, adequate vascular supply, no exposed bone/tendon | Integra Omnigraft (RCT evidence), amniotic membrane allografts (pooled meta-analysis) | | VLU with failed compression therapy | Apligraf has the strongest VLU evidence (pivotal RCT); amniotic membrane allografts used with case series support | | Large wound area requiring coverage | Ambient-storage products typically have lower acquisition cost, improving margin under flat-rate reimbursement | | Wound with biofilm or infection risk | All products require clean wound bed per IFU; none indicated for infected wounds | | Patient preference against animal-derived products | AmnioAMP-MP and Rampart (human amniotic membrane only) vs Integra Omnigraft (bovine + shark) and Apligraf (bovine collagen) | | Wound with exposed bone, tendon, or capsule | Rampart DL Matrix (indicated for exposed tendon/bone); Integra Omnigraft contraindicated for this per DFU labeling |
6.3 Economic Factors (Gate 3)
- Acquisition cost: Obtain current contract pricing; do not rely on list prices - CMS flat rate baseline: Compare each product's net acquisition cost to $127/cm² - Waste frequency: Count products discarded due to expiration, temperature excursion, or damaged packaging - Bundle/packaging: Some manufacturers offer volume discounts or bundled supply agreements - Staff time: Factor in preparation time per application (2 min for in situ hydration vs suture fixation for bilayer matrix vs direct application for living construct)
---
7. Limitations & Caveats
This comparison has several important limitations that readers should consider:
No head-to-head trials exist. No randomized controlled trial has directly compared any two of these four products in the same wound type population. Cross-trial comparisons are inherently confounded by differences in enrollment criteria, wound care protocols, follow-up duration, and outcome definitions. Published evidence is not uniformly current. The pivotal trials for Apligraf (1998, 2001) and Integra Omnigraft for DFU (2015) reflect wound care standards from their respective eras. Wound care practices — including debridement frequency, offloading protocols, infection management, and moisture-retentive dressings — have evolved. Product formulations change. Manufacturers may modify processing methods, sterilization, carrier matrices, or packaging without extensive public notification. Verify current Instructions for Use with each manufacturer. Real-world outcomes vary. Clinical trial outcomes are achieved under controlled conditions with protocol-specified wound care. Real-world results depend on clinician experience, patient compliance, wound bed preparation quality, and treatment frequency. Regulatory status may change. Products cleared under 361 HCT/P status may face reclassification under FDA's ongoing enforcement discretion review. PMA products (Integra Omnigraft, Apligraf) have a different regulatory burden and evidence threshold. Individual patient factors dominate outcomes. Wound healing outcomes are primarily determined by patient comorbidities (glycemic control, vascular status, nutritional status, smoking status), wound characteristics (size, depth, infection, location), and quality of standard wound care — not by product selection alone.---
Sources & References
1. Centers for Medicare & Medicaid Services. CY 2026 Medicare Physician Fee Schedule Final Rule. Federal Register. 2025. 2. Driver VR, et al. A clinical trial of Integra Template for diabetic foot ulcer treatment. Wound Repair Regen. 2015;23(6):891-900. PMID: 26075998. 3. Falanga V, et al. A bilayered living skin construct (Apligraf) accelerates complete closure of hard-to-heal venous ulcers. Dermatol Surg. 1998;24(9):941-947. PMID: 9871984. 4. Veves A, et al. Healing of diabetic foot ulcers with Apligraf. Diabetes Care. 2001;24(2):290-295. PMID: 12766097. 5. Haugh A, et al. Efficacy of a dual-layer pre-hydrated amniotic membrane allograft in the treatment of chronic wounds. J Wound Care. 2025. PMID: 41649915. 6. Zelen CM, et al. A systematic review and meta-analysis of amniotic membrane allografts for diabetic foot ulcers. Wounds. 2025. PMID: 33625595. 7. Organogenesis. Apligraf Package Insert (PMA P950032). Available at: organogenesis.com. 8. Integra LifeSciences. Integra Omnigraft Dermal Regeneration Matrix — Summary of Safety and Effectiveness Data (PMA P900033/S042). 9. Leverage Corp. Rampart DL Matrix product information. Available at: rampartdl.com. 10. NextGen Biologics / Leverage Corp. AmnioAMP-MP Instructions for Use. 11. CMS HCPCS Q-Code Listings (Q4101, Q4105, Q4250, Q4347, C9363). 2026 Update. 12. FDA 21 CFR Part 1271 — HCT/P regulatory framework. 13. SEO research: `nextgenbiologicsusa-seo-research-2026-05-10` — Content gap analysis for wound care comparison content.
---
This guide is an educational resource for clinical decision-making. It does not constitute medical advice, product endorsement, or reimbursement guidance. Reimbursement and coverage policies change frequently. Verify all coding and billing information with your local Medicare Administrative Contractor before submitting claims. Product specifications and clinical claims should be verified with each manufacturer's current Instructions for Use. The products discussed are regulated under different FDA pathways (361 HCT/P, PMA), and clinical evidence levels differ by category and specific product.